JNJ-80948543
As of the edition of 20 October 2026, JNJ-80948543 is a drug known only by a code name: in active development; acts on CD79B and MS4A1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Code name only
- Registered trials
- 4, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 0 | 4 | 0 |
| All trials | 4 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Johnson & Johnson | Lead sponsor of trials | 2022 to now |